From Nerves to Vessels: Unmasking Churg‐Strauss Behind Polyneuropathy Authors: Hiba Antar, Sylvana Balhas, Zeinab El Mawla Published: 2026 ABSTRACT ABSTRACTEosinophilic granulomatosis with polyangiitis (EGPA), formerly Churg‐Strauss vasculitis, is a rare systemic autoimmune disease. Neurological involvement is a significant complication. This report details a case of EGPA with severe, progressive polyneuropathy and atypical serological findings, highlighting diagnostic challenges and the importance of early intervention. A 55‐year‐old male with asthma and uncontrolled diabetes presented with progressive neuropathic pain and paraplegia. He had a history of significant eosinophilia. Clinical examination revealed a rash, neurological deficits, and signs of multisystem involvement. Laboratory tests showed marked eosinophilia, elevated inflammatory markers, renal impairment, and positive ANCA. Imaging revealed cerebral ischemic changes and small vessel vasculitis. A skin biopsy confirmed leukocytoclastic vasculitis, and echocardiography showed cardiac dysfunction. The constellation of symptoms led to a diagnosis of EGPA with multisystem involvement. This case illustrates the classic triad of EGPA symptoms: asthma, hypereosinophilia, and multisystem involvement, particularly neurological. The patient's progressive neurological symptoms and positive ANCA supported the diagnosis of CNS vasculitis. The rapid onset of neurological involvement, despite the patient's age and delayed diagnosis, underscores the aggressive nature of EGPA. The multisystem involvement, including cardiac and renal systems, highlights the need for a comprehensive diagnostic and therapeutic approach. Early diagnosis and aggressive immunosuppressive therapy are crucial for preventing irreversible damage. The atypical finding of c‐ANCA positivity, rather than the more common p‐ANCA, presents a diagnostic challenge and warrants further investigation into specific ANCA subtypes (MPO vs. PR3). This case emphasizes the need for a high index of suspicion for EGPA in patients with unexplained neurological symptoms, especially those with asthma or hypereosinophilia, even in the presence of unusual serological markers. EGPA is a complex disease with diverse neurological and systemic manifestations. This case emphasizes the importance of early recognition and prompt treatment with corticosteroids and immunosuppressive agents to improve patient outcomes and prevent long‐term sequelae. Clinicians should consider EGPA in patients with unexplained neurological symptoms, especially those with a history of asthma or hypereosinophilia. Introduction Churg‐Strauss vasculitis (CSVas), now formally known as eosinophilic granulomatosis with polyangiitis (EGPA), is a rare, systemic autoimmune disease characterized by a triad of clinical features: asthma, hypereosinophilia, and widespread small‐vessel vasculitis [1]. This condition typically manifests in middle‐aged individuals, with an incidence peak observed between 30 and 50 years of age [2]. Neurological involvement, particularly affecting the peripheral nervous system, is a common and significant complication of EGPA, reported in up to 55% of patients [3]. Central nervous system involvement is less frequent but can also occur. This case report details the presentation and successful management of a 55‐year‐old male with a history of asthma and uncontrolled diabetes mellitus who presented with severe, medication refractory neuropathic pain, progressive paraplegia, and markedly elevated serum eosinophil counts. His diagnosis of EGPA was subsequently confirmed, and he responded favorably to treatment with corticosteroids and immunosuppressive therapy. This case is particularly notable due to the severity of neurological involvement, the delayed diagnosis, and the atypical serological finding of c‐ANCA positivity, which posed a diagnostic challenge. Case Presentation Case History/Examination Mr. H., a 55‐year‐old male with no known drug or food allergies, presented with a medical history significant for asthma and uncontrolled diabetes mellitus, complicated by microvascular disease. Approximately 1 year prior to presentation, he began experiencing neuropathic pain, predominantly in his lower extremities, which progressively worsened and proved refractory to conventional neuropathic pain management strategies. During this period, he sought medical attention, and outpatient blood investigations revealed a significant eosinophilia, with a serum eosinophil count of 85%. The patient was admitted to the hospital due to severe, burning pain and tingling sensations in his lower extremities, which had acutely exacerbated over the preceding 2 months. Concurrently, he reported progressive weakness in his legs, culminating in difficulty ambulating and eventual paraplegia. Despite trials of various pain medications, including gabapentin, pregabalin, and duloxetine, no substantial relief was achieved. Upon physical examination, the patient was awake but lethargic and inattentive, exhibiting disorientation to place and time, though he recognized his wife and son. A diffuse erythematous, macular rash was noted on his chest (Figure 1). Erythematous, palpable macular rash were noted on patient's chest. Neurological examination revealed dysarthria, intact oculomotor movements, truncal and limb rigidity, and profound sensory and motor deficits in both upper and lower extremities. An electrocardiogram (ECG) performed on admission demonstrated sinus rhythm with ST‐segment variations. A computed tomography (CT) scan of the brain revealed multiple bilateral scattered focal hypodensities involving the cortico‐subcortical occipital and parietal lobes, as well as the left frontal lobe, suggestive of old ischemic changes of lacunar nature, possibly attributable to embolic causes. The CT also indicated acute‐on‐chronic sinusitis (Figure 2). Noncontrast CT brain of the patient, showing bilateral hypodense lesions suggestive of old ischemic changes. Laboratory investigations were notable for a high white blood cell (WBC) count of 25.6 × 109/L, with a markedly elevated serum eosinophil count of 47.5%. The IgE level was within normal limits. Inflammatory markers were significantly elevated, with an erythrocyte sedimentation rate (ESR) of 126 mm/h and a C‐reactive protein (CRP) of 20 mg/L. Cardiac biomarkers showed an elevated troponin level of 14 ng/dL (normal range < 0.0014 ng/dL). Renal function was impaired, with a creatinine level of 3.4 mg/dL (normal range 0.7–1.3 mg/dL). Urinalysis was significant for positive red blood cell (RBC) casts, proteinuria, and hematuria, indicative of glomerulonephritis. Given the laboratory findings, a CT scan of the abdomen and pelvis was performed to rule out obstructive causes of acute kidney injury, which showed normal kidney size bilaterally and no obstruction. Lung fields on the CT revealed congestion, mild cardiomegaly, mild pericardial effusion, and basal atelectatic changes. A chest X‐ray was clear, with no infiltrates. Considering the patient's history, clinical presentation, and multisystem involvement, an autoimmune panel was drawn. Antineutrophil cytoplasmic antibodies (c‐ANCA) were strongly positive, while the antinuclear antibody (ANA) profile was negative. Other relevant laboratory results are summarized in Table 1. TABLE 1Summary of key laboratory findings.TestLab resultNormal rangeHemoglobin (g/dL)8.914–18Hematocrit (%)22.140–54WBC (109/L)25.634.5–11Segmented (%)41.135–66Lymphocytes (%)8.520–40Basophils (%)00.5–1Eosinophils (%)47.51–4Monocytes (%)2.92–8RDW15.411.8–14.5RBC (1012/L)3.224.35–5.65MCV (fL)86.680–100Platelets (109/L)112150–450PT (s)16.511–13.5INR1.26< 1.1PTT (s)32.125–35ESR (mm/h)126< 15Creatinine (mg/dL)3.40.8–1.1 Summary of key laboratory findings. Brain magnetic resonance imaging (MRI) revealed multiple areas of hyperintensity and hypointensity in the subcortical white matter, consistent with small vessel vasculitis. A focal area of hyperintensity was also noted in the left caudate nucleus, which could be a consequence of vasculitis or an unrelated finding. These findings are highly suggestive of CNS involvement secondary to vasculitis. A skin biopsy obtained from the chest rash demonstrated dermal capillaries outlined by hyperplastic endothelial cells, with narrow lumens and surrounded by a leukocytic exudate composed of mono‐ and polynucleated cells with marked karyorrhexis. Focal and minimal superficial and dermal ischemic changes were also observed on the biopsy. These findings were compatible with leukocytoclastic vasculitis. The biopsy did not specifically detail eosinophilic infiltration, which would have further supported the diagnosis. Nerve Conduction Study (NCS) results showed evidence of severe, asymmetric axonal sensorimotor polyneuropathy, consistent with mononeuritis multiplex, characterized by reduced amplitudes of sensory and motor action potentials with relatively preserved conduction velocities. Transthoracic echocardiography (TTE) revealed an ejection fraction (EF) of 25%–30%, mild dilation of the left ventricle and atrium, moderate global hypokinesia, and Grade I left ventricular diastolic dysfunction. No evidence of thrombosis was detected. Differential Diagnosis, Investigations, and Treatment Based on the comprehensive evaluation of laboratory, imaging, and histological results, the patient was diagnosed with Churg‐Strauss syndrome, now referred to as eosinophilic granulomatosis with polyangiitis (EGPA), with multisystem involvement affecting the skin, renal, cardiac, central nervous system (CNS), and peripheral nervous system (PNS). Classification Criteria for EGPA Applying the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria for EGPA [Reference to ACR/EULAR 2022 criteria], the patient's presentation yields the following score:CriterionScorePatient statusMaximum eosinophil count ≥ 1 × 109/L+5Yes (12.16 × 109/L)Obstructive airway disease (Asthma)+3Yes (history of asthma)Nasal polyps+3Unknown (CT showed sinusitis, but specific nasal polyps not confirmed)Cytoplasmic ANCA (c‐ANCA) or anti‐PR3‐ANCA positivity‐3Yes (c‐ANCA positive)Extravascular eosinophilic predominant inflammation+2Unknown (Skin biopsy showed LCV, but specific eosinophilic infiltration not detailed)Mononeuritis multiplex/motor neuropathy+1Yes (Paraplegia, sensory/motor deficits)Hematuria−1Yes (Urinalysis significant for hematuria) CriterionScorePatient statusMaximum eosinophil count ≥ 1 × 109/L+5Yes (12.16 × 109/L)Obstructive airway disease (Asthma)+3Yes (history of asthma)Nasal polyps+3Unknown (CT showed sinusitis, but specific nasal polyps not confirmed)Cytoplasmic ANCA (c‐ANCA) or anti‐PR3‐ANCA positivity‐3Yes (c‐ANCA positive)Extravascular eosinophilic predominant inflammation+2Unknown (Skin biopsy showed LCV, but specific eosinophilic infiltration not detailed)Mononeuritis multiplex/motor neuropathy+1Yes (Paraplegia, sensory/motor deficits)Hematuria−1Yes (Urinalysis significant for hematuria) Patient's Estimated Score: 5 points. According to the 2022 ACR/EULAR criteria, a score of ≥ 6 is needed for classification of EGPA. While the patient's clinical picture is highly suggestive of EGPA, the formal classification score of 5, primarily due to the negative weighting of c‐ANCA positivity and lack of confirmed nasal polyps or extravascular eosinophilic inflammation, highlights a potential diagnostic challenge. This discrepancy underscores the importance of clinical judgment in conjunction with classification criteria, especially in cases with atypical serological markers. Treatment was initiated with high‐dose corticosteroids and cyclophosphamide. Outcome and Follow‐Up Within a few weeks, the patient exhibited clinical improvement, with a reduction in pain and gradual recovery of motor function in his legs. Concurrently, laboratory findings improved, with a decrease in eosinophil count to 5% and creatinine to 1.3 mg/dL. After 6 months of treatment, the patient was able to eat independently, ambulate with a walker, and reported significantly reduced pain. Discussion Churg‐Strauss vasculitis (CSVas), now known as eosinophilic granulomatosis with polyangiitis (EGPA), is a rare and potentially life‐threatening systemic vasculitis characterized by asthma, hypereosinophilia, and widespread necrotizing small‐vessel vasculitis [4]. Neurological involvement is a common and often debilitating complication of EGPA, with the peripheral nervous system being more frequently affected than the central nervous system [3, 5]. This case report underscores the diverse neurological manifestations of EGPA and emphasizes the critical importance of early diagnosis and prompt treatment to prevent irreversible neurological damage. The patient in this case presented with a classic triad of symptoms highly suggestive of EGPA: asthma, hypereosinophilia, and multisystem involvement. His neurological symptoms, including neuropathic pain, progressive weakness, parkinsonism, and near quadriplegia, are well‐documented manifestations of EGPA [2, 4]. The presence of multiple areas of hyperintensity in the subcortical white matter on brain MRI [6], coupled with a positive ANCA profile, which is more commonly associated with skin rash, neurological involvement, and glomerulonephritis, further supported the diagnosis of CNS vasculitis [2]. The precise timing of PNS involvement in EGPA has not been vividly elucidated in the literature. Chen et al. described a case of a 29‐year‐old male patient who presented with fever and rash on both lower extremities for 18 days, associated with muscle pain and gastrointestinal symptoms [7]. One week after admission, the patient developed distal weakness in both legs, foot drop, cross‐threshold gait, and hypoalgesia on the lateral aspects of both lower legs, all indicative of peripheral nerve damage [7]. The rapid onset of nervous system involvement in this acute setting of EGPA was remarkable, contrasting with many other cases, including ours. Our patient experienced lower limb pain that progressively worsened over several months, eventually leading to paraplegia. However, several factors should be considered in this context, particularly the patient's age, the lack of an accurate diagnosis, the absence of proper treatment, and the consumption of unprescribed medications (gabapentin, pregabalin, duloxetine) during this period. Diagnosing EGPA can be challenging due to its variable clinical presentation and the absence of specific diagnostic tests. Nevertheless, a combination of clinical features, laboratory findings, and histopathology can establish the diagnosis. In this case, the patient's clinical presentation, elevated serum eosinophil count, and positive skin biopsy provided sufficient evidence to confirm the diagnosis of EGPA. Review of the brain imaging results (CT and MRI) revealed affected areas embedded within the subcortical white matter, insinuating small vessel vasculitis, in addition to a focal area in the left caudate nucleus. These findings reflect the profound extent of CNS involvement in EGPA, which can lead to devastating outcomes. In 2023, Kintrilis et al. reported a case of a 59‐year‐old male patient with EGPA who presented with repeated, transient episodes of diplopia and visual loss over several days, alongside asthma and pansinusitis [8]. A temporal artery biopsy showed abundant eosinophils and lymphocytes in the affected areas and arterial wall thickening, paving the way for the rare diagnosis of temporal artery vasculitis as a consequence of EGPA. The visual disturbances rapidly subsided with the initiation of treatment [8]. CNS manifestations in EGPA exhibit a wide spectrum of variation depending on the affected areas. For instance, stroke has been reported as a rare entity in this setting by Huckenpahler et al. in a 69‐year‐old male patient who developed difficulty chewing, initially misinterpreted as temporal arteritis, and later presented with new‐onset weakness and numbness in the right arm [9]. MRI of the brain revealed lacunar infarcts with periventricular hyperintensities [9]. Despite the latter patient having a low risk of stroke, it occurred early in EGPA with a nonspecific presentation. The treatment of EGPA aims to induce remission and prevent relapses. Corticosteroids are the cornerstone of therapy, and immunosuppressive agents such as cyclophosphamide or azathioprine may be employed in patients with refractory disease or recurrent relapses. In this case, the patient was initiated on high‐dose corticosteroids and cyclophosphamide, which resulted in significant improvement in his pain and motor function. Early diagnosis and treatment of EGPA are crucial for preventing irreversible neurological damage. Delayed diagnosis can lead to permanent neurological deficits, including sensory loss, motor impairment, and cognitive decline. Therefore, it is essential for clinicians to consider EGPA in the differential diagnosis of patients with unexplained neurological symptoms, particularly in those with a history of asthma or hypereosinophilia. Prompt initiation of appropriate treatment can significantly improve patient outcomes and reduce the risk of long‐term sequelae. This case report also underscores the importance of recognizing the multisystem nature of EGPA. In addition to neurological involvement, the patient in this case also exhibited elevated cardiac enzyme levels and acute kidney injury, indicating involvement of the cardiovascular and renal systems. This highlights the need for a comprehensive approach to the management of EGPA, with close monitoring of all affected systems. Conclusion In conclusion, EGPA is a complex and potentially devastating disease that can affect multiple organ systems, including the nervous system. Early diagnosis and prompt initiation of treatment with corticosteroids and immunosuppressive agents are essential for preventing irreversible neurological damage and improving patient outcomes. Clinicians should maintain a high index of suspicion for EGPA in patients presenting with unexplained neurological symptoms, especially those with a history of asthma or hypereosinophilia. Prompt recognition and comprehensive management of EGPA can significantly enhance patient quality of life and mitigate the risk of long‐term sequelae. Author Contributions Hiba Antar: conceptualization, data curation, formal analysis, investigation, methodology, project administration, writing – original draft. Sylvana Balhas: conceptualization, formal analysis, investigation, methodology, project administration, writing – original draft. Zeinab El Mawla: conceptualization, data curation, project administration, supervision, validation, visualization, writing – review and editing. Funding The authors have nothing to report. Ethics Statement The authors have nothing to report. Consent Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review upon request by the Editor‐in‐Chief of this journal. Conflicts of Interest The authors declare no conflicts of interest.